The efficacy and safety of toripalimab in combination with lenvatinib and TACE for conversion therapy in patients with potentially resectable hepatocellular carcinoma: A prospective, multicenter, single-arm Phase II study

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 70af3a5e53055df9e5aaefd87ff91f0dc4eec540
First added on: Oct 10, 2026